Giovannoni G, et al. Treatment outcomes of daclizumab in patients at high risk of transitioning to secondary progressive multiple sclerosis in DECIDE. EAN 2107, O2113.
RAS-ALS: Effectiviteit van rasagiline in subgroepen
mrt 2024 | Bewegingsstoornissen